0
Editorials |

Identifying and Treating COPD in Cardiac PatientsCOPD and Cardiovascular Diseases

Carlo Nozzoli, MD; Bianca Beghè, MD, PhD; Piera Boschetto, MD, PhD; Leonardo M. Fabbri, MD, FCCP
Author and Funding Information

From the Department of Internal Medicine (Dr Nozzoli), Azienda Ospedaliera Careggi; the Department of Medical and Surgical Sciences (Drs Beghè and Fabbri), University of Modena and Reggio Emilia, AOU Policlinico di Modena; and Department of Medical Sciences (Dr Boschetto), University of Ferrara, AOU S. Anna di Ferrara.

Correspondence to: Leonardo M. Fabbri, MD, FCCP, University of Modena and Reggio Emilia, Department of Medical and Surgical Sciences, AOU Policlinico di Modena, Via del Pozzo 71, 41124 Modena, Italy; e-mail: leonardo.fabbri@unimore.it


Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Fabbri received payment for consultancy from: Almirall SA, Boehringer Ingelheim GmbH, Chiesi Farmaceutici, Euromediform, GlaxoSmithKline, Merck Sharp & Dohme Corp, Mundipharma International, Novartis Corporation, Takeda Pharmaceuticals International GmbH, Parexel International Corp, Pearl Therapeutics Inc, Sterna Biologicals GmbH & Co, PeerVoice Europe, Vifor Pharma Ltd, Teva Pharmaceuticals Industries Ltd; payment for lectures, advisory boards, or travel expense reimbursements from AstraZeneca, Grünenthal, Mundipharma International, Novartis Corporation, F. Hoffman-La Roche Ltd, Genentech Inc, Sunovion Pharmaceuticals Inc, and Ferrer Internacional. Dr Beghè received payment for lectures or travel expense reimbursements from AstraZeneca, Menarini, Chiesi Farmaceutici, Takeda Pharmaceuticals International GmbH; and payment for development of educational presentations from Takeda Pharmaceuticals International GmbH. Drs Nozzoli and Boschetto have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

Funding/Support: The authors are supported by Associazione per lo Studio dei Tumori e delle Malattie Polmonari (Padova, Italy); Consorzio Ferrara Ricerche (Ferrara, Italy); and Associazione per la Ricerca e la Cura dell’Asma (Padova, Italy), Italian Ministry of Health (CCM grant).

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.


Chest. 2013;144(3):723-726. doi:10.1378/chest.13-0915
Text Size: A A A
Published online

Extract

COPD1 and coronary artery disease (CAD),2 also known as atherosclerotic heart disease, are highly prevalent worldwide, with rates increasing with the aging of the population.3,4 By 2030, COPD is expected to be the direct underlying cause of 7.8% of all deaths and 27% of deaths due to smoking—surpassed only by cancer (33%) and cardiovascular disease (29%).3,4 By contrast, death from CAD, both in midlife and at older ages, has been decreasing in Western Europe and the United States since 1970; furthermore, survival after acute events has improved. The prevalence of CAD remains high in developing countries and has increased in some parts of the population (eg, older women). Thus, the impact of COPD and CAD on health remains huge, and, given the frequency of the two diseases and their common causal factors, notably smoking, the probability that they coexist in a given patient is very high.3,4

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543